Drug profile · INN
vericiguat
VERQUVO
vericiguat (VERQUVO) is a soluble guanylate cyclase activator. Associated with Bayer Australia Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — vericiguat
- US status
- approved
- Class
- Cardiovascular system (C01)
- Route
- ORAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
vericiguat (VERQUVO) is a soluble guanylate cyclase activator. Associated with Bayer Australia Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Soluble guanylate cyclase activator
Primary target: Soluble guanylate cyclase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is vericiguat?
vericiguat (VERQUVO) is a soluble guanylate cyclase activator. Associated with Bayer Australia Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for vericiguat?
VERQUVO is a marketed brand name for vericiguat. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of vericiguat?
vericiguat has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.